Abstract: The present invention relates to antibody derivatives against HIV based on a mutated CD4-IgG scaffold with enhanced antiviral and immunomodulatory activities. These antibody derivatives are characterized for having an increased ability to (i) block the entry of human immunodeficiency virus (HIV) into host cells and (ii) elicit effector functions through the activation, of natural killer (NK) cells. The present invention further relates to nucleic acids, vectors and host cells expressing said antibody derivatives, as well their therapeutic and diagnostic applications in human health.

Abstract: Fc-fusion protein derivatives against HIV have enhanced yield in mammalian cells, and extended antiviral and immunomodulatory activities. The Fc-fusion protein derivatives can block the entry of human immunodeficiency virus (HIV) into host cells, elicit effector functions through the activation of natural killer (NK) and other immune system cells, can be produced with high yield in mammalian cells, and have extended activity in vivo. Nucleic acids, vectors and host cells can express the Fc-fusion protein derivatives, which have therapeutic and diagnostic applications in human health.

Abstract: A power bank system includes a packaging container and a power bank. The packaging container defines an internal cavity and has an external receiving surface. The power bank has a battery, a primary coil, and a sensor. The power bank is positioned within the internal cavity such that the primary coil and the sensor are disposed proximate to an opposing side of the external receiving surface. The external receiving surface is configured to receive a portable device. The power bank is configured to deliver power from the battery to the portable device wirelessly via the primary coil and though the external receiving surface in response to the sensor detecting the portable device being positioned proximate the external receiving surface.

Abstract: A power bank system includes a packaging container and a power bank. The packaging container defines an internal cavity and has an external receiving surface. The power bank has a battery, a primary coil, and a sensor. The power bank is positioned within the internal cavity such that the primary coil and the sensor are disposed proximate to an opposing side of the external receiving surface. The external receiving surface is configured to receive a portable device. The power bank is configured to deliver power from the battery to the portable device wirelessly via the primary coil and though the external receiving surface in response to the sensor detecting the portable device being positioned proximate the external receiving surface.

Abstract: A power bank system includes a packaging container and a power bank. The packaging container defines an internal cavity and has an external receiving surface. The power bank has a battery, a primary coil, and a sensor. The power bank is positioned within the internal cavity such that the primary coil and the sensor are disposed proximate to an opposing side of the external receiving surface. The external receiving surface is configured to receive a portable device. The power bank is configured to deliver power from the battery to the portable device wirelessly via the primary coil and though the external receiving surface in response to the sensor detecting the portable device being positioned proximate the external receiving surface.

Abstract: The present invention relates to antibody derivatives against HIV based on a mutated CD4-IgG scaffold with enhanced antiviral and immunomodulatory activities. These antibody derivatives are characterized for having an increased ability to (i) block the entry of human immunodeficiency virus (HIV) into host cells and (ii) elicit effector functions through the activation of natural killer (NK) cells. The present invention further relates to nucleic acids, vectors and host cells expressing said antibody derivatives, as well their therapeutic and diagnostic applications in human health.

Abstract: The invention relates to a fusion protein comprising a polypeptide of interest, a transmembrane domain and an HIV gag polypeptide, or their functionally equivalent variants. The invention also relates to the polynucleotides, vectors, host cells and virus-like particles expressing or presenting said fusion proteins and to the pharmaceutical, immunogenic or vaccines composition containing said fusion proteins, polynucleotides, vectors, host cells and virus-like particles and their use in human and veterinary medicine.

Abstract: Fc-fusion protein derivatives against HIV have enhanced yield in mammalian cells, and extended antiviral and immunomodulatory activities. The Fc-fusion protein derivatives can block the entry of human immunodeficiency virus (HIV) into host cells, elicit effector functions through the activation of natural killer (NK) and other immune system cells, can be produced with high yield in mammalian cells, and have extended activity in vivo. Nucleic acids, vectors and host cells can express the Fc-fusion protein derivatives, which have therapeutic and diagnostic applications in human health.

Abstract: The invention relates to a fusion protein comprising a polypeptide of interest, a transmembrane domain and an HIV gag polypeptide, or their functionally equivalent variants. The invention also relates to the polynucleotides, vectors, host cells and virus-like particles expressing or presenting said fusion proteins and to the pharmaceutical, immunogenic or vaccines composition containing said fusion proteins, polynucleotides, vectors, host cells and virus-like particles and their use in human and veterinary medicine.

Abstract: The present invention relates to an in vitro method for determining HIV neutralizing antibodies in a sample. It further relates to a fusion protein to be used in said method and a nucleic acid encoding said fusion protein.

Abstract: The present invention relates to an in vitro method for determining HIV neutralizing antibodies in a sample. It further relates to a fusion protein to be used in said method and a nucleic acid encoding said fusion protein.

Abstract: The present invention provides a nixtamalization process wherein corn endosperm fractions, subfractions, or combinations thereof are individually nixtamalized to produce food products. The invention also comprises food products, including masa, instant masa, tortillas, and tortilla-related food products produced by the present invention's methods, including food products that have controllable fat and/or fiber levels.